BBA
PACB icon

Baker Bros. Advisors’s Pacific Biosciences PACB Stock Holding History

Baker Bros. Advisors’s Portfolio PACB Stock Details PACB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-1,127,782
Closed -$9.42M – 96
2023
Q3 		$9.42M Hold
1,127,782
– – 0.05% 46
2023
Q2 		$15M Hold
1,127,782
– – 0.09% 48
2023
Q1 		$13.1M Hold
1,127,782
– – 0.07% 45
2022
Q4 		$9.23M Hold
1,127,782
– – 0.06% 61
2022
Q3 		$6.55M Sell
1,127,782
-4,317,181
-79% -$24.8M 0.04% 69
2022
Q2 		$24.1M Hold
5,444,963
– – 0.14% 43
2022
Q1 		$49.5M Hold
5,444,963
– – 0.28% 28
2021
Q4 		$111M Hold
5,444,963
– – 0.54% 17
2021
Q3 		$139M Buy
5,444,963
+2,242,991
+70% +$66.5M 0.61% 16
2021
Q2 		$112M Hold
3,201,972
– – 0.49% 20
2021
Q1 		$107M Hold
3,201,972
– – 0.46% 20
2020
Q4 		$83.1M Sell
3,201,972
-48,028
-1% -$816K 0.31% 22
2020
Q3 		$32.1M Buy
+3,250,000
New +$18.7M 0.13% 40

Other funds holding PACB

AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
MA
Madrone Advisors Menlo Park, California $1.03B AUM 20.53% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return
JSP
Jackson Square Partners Larkspur, California $247M AUM 20.29% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

Baker Bros. Advisors's PACB Position: Q4 2023 in Review

Baker Bros. Advisors sold out of Pacific Biosciences (PACB) in Q4 2023, closing a stake of 1,127,782 shares — an estimated $9.42M sold.

Baker Bros. Advisors first reported a position in PACB in Q3 2020 and held it in 13 quarters. The position peaked at $139M in Q3 2021. 274 funds tracked by Wall St. Rank hold PACB as of Q4 2023.

  • Baker Bros. Advisors reported no remaining Pacific Biosciences position as of Q4 2023 after selling out during the quarter.
  • Baker Bros. Advisors sold 1,127,782 Pacific Biosciences shares in Q4 2023, an estimated $9.42M.
  • Baker Bros. Advisors first reported a position in Pacific Biosciences in Q3 2020 and held it in 13 quarters.
  • Baker Bros. Advisors's Pacific Biosciences position peaked at $139M in Q3 2021.
  • 274 funds tracked by Wall St. Rank held Pacific Biosciences as of Q4 2023.

Based on Baker Bros. Advisors's 13F filing for Q4 2023, filed 14 Feb 2024.